Announcements Trials
Browse Landscape

Status

Recruiting 12Active not recruiting 8Not yet recruiting 2Enrolling by invitation 1Completed 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Sarcoma 5Recurrence 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Neuroblastoma 4Multiple Myeloma 4Breast Neoplasms 4Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Insulinoma 2Hypoglycemia 2Hyperinsulinism 2

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Neurofibroma, Plexiform × 1 year × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡